Search - tctmd.com

Displaying 81 - 100 of 100

Sort: Relevancy | Date

News Daily News

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

Michael O'Riordan

January 19, 2018

News Conference News AHA 2017

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Michael O'Riordan

November 17, 2017

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Todd Neale

November 14, 2017

News Daily News

More CVD and Stroke Drive Shorter Life Spans in African-Americans: AHA

Michael O'Riordan

October 24, 2017

News Daily News

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

Michael O'Riordan

October 20, 2017

News Daily News

NOAC Bleeding Risk Rises With Several Drug Combinations

Michael O'Riordan

October 06, 2017

Presentation VIVA 2017

Is Aspirin Really a Class I Medication in Peripheral Artery Disease?

Presenter: Ehrin J. Armstrong

September 19, 2017

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

Todd Neale

August 27, 2017

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

Shelley Wood

August 18, 2017

News Daily News

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

Leah Lawrence

August 01, 2017

News Daily News

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

Leah Lawrence

July 24, 2017

News Daily News

3-D Ultrasound Quantifies Plaque Burden in Healthy Middle-Aged Cohort

Michael O'Riordan

July 11, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Rivaroxaban’s ‘Overwhelming’ Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

Todd Neale

February 08, 2017

News Conference News ESC 2016

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

Michael O'Riordan

August 27, 2016

News Daily News

Underuse of Medical Therapy Linked With Increased Adverse Events in Very Elderly

Michael O'Riordan

July 21, 2016

News Industry News

Symic Biomedical Selects Vascular Clinical Candidate

July 20, 2015

News Daily News

Risk Factor Control Linked to Better Outcomes After Peripheral Intervention

Caitlin E. Cox

December 16, 2012

News Daily News

El Control del Factor de Riesgo se asocia a Mejores Resultados tras una Intervención Periférica

Caitlin E. Cox

December 16, 2012

Advertisement

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

More CVD and Stroke Drive Shorter Life Spans in African-Americans: AHA

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

NOAC Bleeding Risk Rises With Several Drug Combinations

Is Aspirin Really a Class I Medication in Peripheral Artery Disease?

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

3-D Ultrasound Quantifies Plaque Burden in Healthy Middle-Aged Cohort

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Rivaroxaban’s ‘Overwhelming’ Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

Underuse of Medical Therapy Linked With Increased Adverse Events in Very Elderly

Symic Biomedical Selects Vascular Clinical Candidate

Risk Factor Control Linked to Better Outcomes After Peripheral Intervention

El Control del Factor de Riesgo se asocia a Mejores Resultados tras una Intervención Periférica

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content